ArticleMolecular psychiatry2026
hiPSC-derived cortical neurons from ADHD individuals reveal dysregulated glutamatergic development.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dissecting the shared genetic architecture between testosterone traits and attention-deficit/hyperactivity disorder.European child & adolescent psychiatry · 2026Article
- Algae-Derived Peptides as Functional Food Ingredients: Bioactivities, Processing Challenges, and Computational Design Strategies.Foods (Basel, Switzerland) · 2026Review
- The effects of omega-3 fatty acids on Wnt activity in iPSC-derived neural stem cells from adult ADHD patients.Neuroscience applied · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder characterised by inattention, hyperactivity, and impulsivity, significantly impacting life quality and mortality. It is among the most heritable neuropsychiatric disorders, yet its aetiology remains unclear, hindering the development of novel medications. Previously, research has primarily focused on the dopaminergic and noradrenergic systems using animal models. However, there is growing evidence for a role of the glutamatergic system in ADHD pathomechanisms, and a translational failure between pre-clinical animal models and human clinical trials. We therefore established and characterised a functional cortical neuronal model using human induced pluripotent stem cells (hiPSCs) to investigate glutamatergic development in healthy controls and adult ADHD patients. hiPSCs from healthy controls and ADHD patients showed no difference in their capacity to form cortical neurons (CNs). However, CNs from ADHD patients showed an altered developmental pattern, characterised by changes in extracellular glutamate and decreased transcription of NEUN, PSD95 and EEAT2. Moreover, a significant ~50% reduction in vGLUT2 transcription was observed at multiple time points, suggesting a robust cellular disease endophenotype which might be suitable for future drug screening. Lastly, calcium imaging analysis revealed decreased synaptic signalling strength and frequency, indicating a hypoactive phenotype. In summary, we were able to establish a functional hiPSC-derived cortical neuronal model to investigate ADHD pathomechanisms, which revealed impaired glutamatergic development in ADHD individuals. Our results suggest that the glutamatergic system should also be a target for future drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.